buy nik software cheap rosetta stone at best buy buy word for mac online cost of dreamweaver 8 purchase ms office for mac cheap windows 7 genuine retail key where can i buy powerpoint 2003 buy photoshop cs4 extended student purchase office 2007 professional buy microsoft money plus deluxe buy 2007 office pro buy autodesk autocad architecture 2015 64bit best price outlook 2007 business contact manager best buy office professional plus 2010 price of adobe photoshop cc 2014
buy bento 3 online buy microsoft project 2010 student discount office 2013 home and business buy microsoft outlook 2003 oem windows 2008 enterprise cost best buy pinnacle studio 15 purchase microsoft outlook 2003 buy server 2003 standard edition windows 7 discount price buy reason 4.0 upgrade buying microsoft outlook 2003 purchase office 2007 home buying autocad architecture 2008 buy adobe cs2 package buy nero media home

Cancer Prevention Research

Mon, Nov 25, 2013

Oral Cancer News


Clinical and biochemical studies support smokeless tobacco’s carcinogenic potential in the human oral cavity

Source: American Association of Cancer Research
Published: November 9, 2013
By: Susan R. Mallery, Meng Tong, Gregory C. Michaels, Amber R. Kiyani, and Stephen S. Hecht



In 2007, International Agency for Cancer Research presented compelling evidence that linked smokeless tobacco use to the development of human oral cancer. While these findings imply vigorous local carcinogen metabolism, little is known regarding levels and distribution of Phase I, II and drug egress enzymes in human oral mucosa. In the study presented here, we integrated clinical data, imaging and histopathologic analyses of an oral squamous cell carcinoma that arose at the site of smokeless tobacco quid placement in a patient. Immunoblot and immunohistochemical (IHC) analyses were employed to identify tumor and normal human oral mucosal smokeless tobacco-associated metabolic activation and detoxification enzymes. Human oral epithelium contains every known Phase I enzyme associated with nitrosamine oxidative bioactivation with ~2 fold inter-donor differences in protein levels. Previous studies have confirmed ~3.5 fold inter-donor variations in intraepithelial Phase II enzymes. Unlike the superficially located enzymes in non-replicating esophageal surface epithelium, IHC studies confirmed oral mucosal nitrosamine metabolizing enzymes reside in the basilar and suprabasilar region which notably is the site of ongoing keratinocyte DNA replication. Clearly, variations in product composition, nitrosamine metabolism and exposure duration will modulate clinical outcomes. The data presented here form a coherent picture consistent with the abundant experimental data that links tobacco-specific nitrosamines to human oral cancer.


* This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.


Print Friendly
Be Sociable, Share!
, , ,

Leave a Reply

You must be logged in to post a comment.